pharmaceutical industry

See the following -

'Moral Bankruptcy of Capitalism': UK’s Top Public Doctor Shames Western Society Over Ebola

Staff Writer | RT News | August 3, 2014

Western countries should tackle drugs firms’ “scandalous” reluctance to invest in research into the virus which has already killed over 700 people in West Africa, the UK’s top public doctor said, adding, “They’d find a cure if Ebola came to London.” The pharmaceutical industry are reluctant to invest in research to produce treatments and vaccines “because the numbers involved are, in their terms, so small and don't justify the investment,” said Professor John Ashton, president of the UK Faculty of Public Health, an independent body for specialists in public health in the United Kingdom. Read More »

A Few Thoughts About The Health-Care Marketplace

Jeanne Pinder | Clear Health Costs | February 27, 2013

Is it time for rate-setting in the health-care marketplace? Is it time for single-payer health care? Or an end to the entire for-profit system of mis-aligned incentives? Or transparency? Can we continue in this vein? Read More »

A Law Professor’s Big Idea for Combating Greedy Drug Company Titans Like Martin Shkreli

Noah Berlatsky | Quartz | September 21, 2017

In 2015, CEO of Turing Pharmaceuticals Martin Shkreli infamously raised the price of the life-saving drug Daraprim by 5,000%. Daraprim, developed more than 60 years ago, is used to treat the deadly parasitic infection toxoplasmosis. It was selling for $13.50 a pill; then Turing raised the price to $750. The move sparked massive backlash and Congressional hearings, and Shkreli himself was eventually arrested for, and convicted of, unrelated securities fraud charges. But the original, horrible problem didn’t get fixed. Turing kept the price sky-high; as of August 2016, many patients were paying $375 per pill...

Read More »

A Way For Biopharma To Disclose More Trial Data

Ken Getz | Medical Marketing & Media | December 26, 2012

[...] At a time when some regulatory bodies and biopharma companies are increasing their transparency initiatives involving access to clinical-trial data, disclosing trial results to volunteers could also go a long way toward strengthening public confidence. Read More »

Across Pharma, Few Open Arms For Trial Data Sharing

Alex Philippidis | Genetic Engineering & Biotechnology News (GEN) | July 9, 2013

Industry inches toward consensus on limited sharing as EMA, GSK press for open access. Read More »

Advancing Antimalarial Drug Research Through Open Source Initiatives

Jeremy Burrows | The Guardian | July 24, 2013

Open research can lead to new drugs tackling diseases that afflict the world's poor. But first, more scientists need to buy into contributing to something bigger than their careers Read More »

Antibiotic-Resistant Diseases Pose 'Apocalyptic' Threat, Top Expert Says

Ian Sample | The Guardian | January 23, 2013

Chief medical officer Dame Sally Davies tells MPs issue should be added to national risk register of civil emergencies Read More »

Bad Pharma: Account Of The Bottomless Corruption Of The Pharma Industry Is A Stirring Call To Arms

Cory Doctorow | Boing Boing | November 6, 2012

I mentioned in September that Ben "Bad Science" Goldacre had a new book out, Bad Pharma: How drug companies mislead doctors and harm patients. I was sure at the time that this would be the usual excellent Goldacre fare -- lucid, thorough, and important. Now that I'm back from my own book tour, I've had a chance to read it and I'm pleased (or rather, furious -- more on this later) to report that this really is the usual, excellent Goldacre stuff. Read More »

Before The Prescription, Ask About Your Doctor's Finances

Leana Wen | Capital Public Radio | December 16, 2013

At the dawn of managed care, worried patients wanted to know whether their doctors were getting paid more to do less. Now, as many doctors' salaries depend on how many procedures they perform, patients want to know whether their doctors are paid more to do more. Read More »

Big Pharma Opens New Chapter On Big Data Collaboration

Dan Munro | Forbes.com | April 8, 2014

In the course of one short week, no less than 3 different models have emerged for sharing big data in the pharmaceutical industry.  The highest profile of these ‒ called Project Data Sphere (PDS here) ‒ was announced earlier today with the official opening of an online resource to share clinical trial data for use in cancer research.

Read More »

Big Pharma Won’t Let Your Doctor Forget Your Next Shot

Rachel Feltman | Quartz | May 3, 2014

The pharmaceutical company Merck wants to make sure you get your recommended vaccinations on time, and not just for your own good. The company’s partnership with Practice Fusion, the largest online platform for electronic medical record management in the US, will provide physicians with reminders when their patients are due for a vaccination by the Centers for Disease Control’s standards...

Read More »

Brand-Name Drugs Pushing Up US Medicare Costs: Survey

Lynne Taylor | PharmaTimes | June 12, 2013

People with diabetes who are enrolled in the US federal Medicare health programme are two to three times more likely to use "expensive" brand-name drugs than diabetes patients who are treated within the Veterans Administration (VA) Healthcare System, new research shows. Read More »

Business and Medical Leaders Develop Crowdsourced Platform to Solve Complex Immunological Problems

Ravi Parikh | Medgadget | April 8, 2013

Here at Medgadget, we have previously covered efforts to crowdsource ideas for developing medical technology and innovation. For example, we have seen programs that crowdsource retinal connectome mapping and protein folding. Read More »

Can GAVI’s New Partnership Model Crack ‘mhealth Pilotitis’ While Opening New Markets For Vodafone?

Stephanie Hanson | devex.com | August 21, 2013

In the 13 years since it was founded to jumpstart stagnating global vaccination rates, the GAVI Alliance has achieved some remarkable results. Read More »

Cancer And Clinical Trials: The Role Of Big Data In Personalizing The Health Experience

Despite considerable progress in prevention and treatment, cancer remains the second leading cause of death in the United States. Even with the $50 billion pharmaceutical companies spend on research and development every year, any given cancer drug is ineffective in 75% of the patients receiving it. [...] Read More »